spacer
home > epc > autumn 2003 > editor's letter
PUBLICATIONS
European Pharmaceutical Contractor

Editor's Letter

I am writing this Editor's Letter in the middle of a British heatwave; and this time we really can call it a heatwave, with temperatures soaring over 30oC, and railway lines buckling! Temperatures are currently similar to those in San Antonio in June, where the 39th Annual DIA meeting was held. This meeting continues to grow in size, and this year it was bigger than ever, my only complaint being that there wasn't enough time to visit all the exhibition stands and attend all but a sample of the sessions.

I did, however, attend several of the sessions relating to outsourcing, but was disappointed that there seems to be little progress in improving the relationship between CRO and sponsor. The 'Preferred Provider Tug of War' was one title, which gives an idea of how the relationship is often viewed. The presentations supporting this title addressed how to make

it less of a struggle, and in a different session, classified as R&D Strategy, we heard about a strategic partnership between Solvay and Quintiles, which highlights how the sponsor/CRO relationship can develop to the benefit of both parties.

Included in this issue we have an article by Blair McCallum of McKinsey that describes the assessments of the benefits of outsourcing. While this article focuses on manufacturing, the 10 commandments given at the end could apply to any outsourcing relationship. The keys are clear communication, understanding the value proposition and clearly stated plans.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Julia Lloyd-Parks
spacer
Julia Lloyd-Parks
spacer
spacer
spacer
John White
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization (CDMO), celebrates its 15th anniversary today. As a midsized CDMO, Northway Biotechpharma is able to provide flexibility and responsiveness backed by a strong foundation in science and technology. The company focuses on understanding its customers and meeting their specific needs without binding them to one single approach. It is able to react rapidly to unexpected project changes, adjusting timelines, capacities and other activities to meet its customers’ evolving needs. On average, Northway Biotechpharma has 25–30 development projects underway each year, ranging from gene cloning to final drug product manufacturing.
More info >>

White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement